Medicinova Inc (OQ:MNOV)

Apr 02, 2024 07:00 pm ET
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (20
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a clinical trial of MN-166...
Mar 26, 2024 07:00 pm ET
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Japan Patent...
Mar 20, 2024 07:00 pm ET
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that two abstracts entitled “STUDY PROTOCOL TO EVALUATE MN-001’S...
Mar 12, 2024 06:30 am ET
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Perenlei Enkhbaatar, MD, PhD,...
Jan 17, 2024 06:00 am ET
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Grant from the Chinese Patent...
Dec 21, 2023 06:00 pm ET
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a nonclinical study of...
Dec 06, 2023 06:00 pm ET
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Decision to Grant from the European...
Nov 20, 2023 08:31 am ET
Thinking about buying stock in Macy's, Marathon Digital, Medicinova, Telecom Argentina, or Nuscale Power?
NEW YORK, Nov. 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for M, MARA, MNOV, TEO, and SMR.
Nov 19, 2023 06:00 pm ET
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Justin Lathia PhD, Co-Director...
Oct 27, 2023 01:00 am ET
MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that its collaborator Genzyme Corporation, a subsidiary of...
Oct 10, 2023 07:00 pm ET
MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Canadian...
Oct 04, 2023 07:00 pm ET
MediciNova Receives Gene Therapy Milestone Payment
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a milestone payment under MediciNova’s...
Sep 27, 2023 07:00 pm ET
MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the results of the nonclinical studies conducted under its...
Aug 17, 2023 07:00 pm ET
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding tumor tissue analysis data from a...
Aug 16, 2023 07:00 pm ET
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Intention to Grant from the European...
Aug 15, 2023 07:00 pm ET
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Decision to Grant from the European Patent...
Aug 14, 2023 07:00 pm ET
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Intention to Grant from the European...
Jun 29, 2023 06:00 am ET
MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Principal Investigator, Lara Ray, PhD, Professor,...
May 14, 2023 07:00 pm ET
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Intention to Grant from the European...
Apr 30, 2023 07:00 pm ET
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Canadian...
Mar 09, 2023 06:00 pm ET
MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced a modification to its contract with the Biomedical Advanced...
Feb 20, 2023 06:00 pm ET
MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s research collaborator, Justin Lathia, PhD,...
Feb 08, 2023 06:00 pm ET
MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Health Canada has completed its review of the clinical trial...
Jan 30, 2023 06:00 pm ET
MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Phase 2b clinical trial evaluating MN-166 (ibudilast) for...
Jan 12, 2023 06:00 pm ET
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Phase 2 clinical trial evaluating MN-166 (ibudilast) in...
Jan 10, 2023 10:00 pm ET
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Canadian...
Jan 09, 2023 10:00 pm ET
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Brazilian Patent...
Jan 05, 2023 06:00 pm ET
MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a Phase I clinical trial to evaluate MN-166 (ibudilast) 10 mg...
Dec 06, 2022 06:00 pm ET
MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meet
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s Chief Medical Officer, Kazuko Matsuda, MD PhD...
Dec 05, 2022 06:00 pm ET
MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive results from a secondary analysis of a Phase 2 trial...
Sep 15, 2022 07:00 pm ET
MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will be conducting one-on-one virtual meetings with...
Sep 14, 2022 07:00 pm ET
MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received an Issue Notification from the U.S. Patent...
Sep 13, 2022 07:00 pm ET
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Canadian...
Aug 16, 2022 06:30 am ET
MediciNova Reaches Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVID
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to participate in RECLAIM (Recovering from COVID-19...
Aug 09, 2022 07:00 pm ET
MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meetin
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an abstract entitled “Improvement of Serum Lipid Panel by...
Jul 27, 2022 06:30 am ET
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Korean...
Jul 26, 2022 06:30 am ET
MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the initiation of a Phase 2 clinical trial to evaluate MN-001...
Jul 21, 2022 07:00 pm ET
MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the initiation of a first-in-human clinical study to evaluate the...
Jun 29, 2022 07:00 pm ET
MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced a modification to its contract with the Biomedical Advanced...
Jun 22, 2022 07:00 pm ET
MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a comprehensive research collaboration with...
Jun 08, 2022 06:30 am ET
MediciNova Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive top-line results from MediciNova’s Phase 2 clinical...
Apr 21, 2022 07:00 pm ET
MediciNova to Participate in the B. Riley Neuro & Ophthalmology Conference
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer,...
Apr 20, 2022 07:00 pm ET
MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced data demonstrating that MN-166 (ibudilast) prevents metastasis in...
Apr 12, 2022 11:00 pm ET
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Phase 2 clinical trial of MN-166 (ibudilast) in...
Apr 11, 2022 06:30 am ET
MediciNova Announces Plans for a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the U.S. Food and Drug Administration (FDA) has completed...
Apr 07, 2022 07:00 pm ET
MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a secondary analysis of a Phase 2 clinical trial of MN-166...
Mar 17, 2022 06:30 am ET
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Korea
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Korean...
Mar 15, 2022 06:30 am ET
MediciNova to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Geoffrey O'Brien, JD/MBA, Vice President and Executive...
Feb 28, 2022 06:30 am ET
MediciNova Announces MN-166 (ibudilast) Identified as Potential Beneficial Pharmacotherapy for Treatment of Degenerative Cervical Myelopathy in Global Spine Journal
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MN-166 (ibudilast) was discussed as a potential beneficial...
Feb 22, 2022 06:30 am ET
MediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced MN-166 (ibudilast) was discussed as one of the promising...
Feb 01, 2022 07:31 am ET
Thinking about buying stock in AMC Entertainment, Spire Global, Lucid Group, MediciNova, or Palantir Technologies?
NEW YORK, Feb. 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, SPIR, LCID, MNOV, and PLTR.
Feb 01, 2022 06:30 am ET
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Korea
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a new patent from the Korean Intellectual...
Jan 31, 2022 06:30 am ET
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Canadian...
Jan 27, 2022 06:30 am ET
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to Grant from...
Jan 26, 2022 06:30 am ET
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Europe
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to Grant from...
Dec 13, 2021 06:30 am ET
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent...
Dec 10, 2021 06:30 am ET
MediciNova Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Dr. Malath Makhay, Director, Scientific Affairs, presented...
Nov 23, 2021 09:55 am ET
Thinking about buying stock in Tonix Pharmaceuticals, New Oriental Education, Marathon Oil, American Eagle Outfitters, or MediciNova?
NEW YORK, Nov. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TNXP, EDU, MRO, AEO, and MNOV.
Nov 22, 2021 06:30 am ET
MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma Presented at the 26th Annual Meeting of the Society for Neuro-Oncology
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s research collaborator, Justin Lathia PhD,...
Nov 11, 2021 06:00 pm ET
MediciNova Announces MN-001 (tipelukast) Data regarding Lipid Metabolism in NASH/NAFLD to be Presented at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s research collaborator Masatsune Ogura, M.D.,...
Nov 10, 2021 06:00 pm ET
MediciNova Announces New Data regarding MN-166 (ibudilast) in Uveal Melanoma Presented at the CURE OM Global Science Meeting
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Grazia Ambrosini, PhD, an associate research scientist at...
Nov 03, 2021 07:30 pm ET
MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma to be Presented at the Annual Meeting of the Society for Neuro-Oncology
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Dr. Justin Lathia, Co-Director of...
Oct 21, 2021 06:30 am ET
MediciNova Announces Abstract regarding the Mechanism by which MN-001 (tipelukast) Alters Triglyceride Metabolism Accepted for Presentation at the 19th International Symposium on Atherosclerosis (ISA2
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an abstract entitled “MN-001 (tipelukast) reduces triglycerides...
Sep 02, 2021 11:00 pm ET
MediciNova to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will participate in the virtual Morgan Stanley...
Sep 01, 2021 06:30 am ET
MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting® 2021, the Annual Meeting of the American Association for the
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an abstract entitled “Improvement of Intracellular Lipid...
Aug 30, 2021 06:30 am ET
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding MediciNova’s ongoing Phase 2b/3...
Aug 12, 2021 07:00 pm ET
MediciNova Reports Second Quarter 2021 Financial Results and Business Update
MediciNova, Inc., (Nasdaq: MNOV, JASDAQ:4875), a biopharmaceutical company developing small-molecule therapeutics, today reported financial results for the second quarter ended June 30, 2021 and provided a business update including results of a...
Jul 06, 2021 06:30 am ET
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Ophthalmic Disease
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent...
Jun 29, 2021 06:30 am ET
MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer,...
Jun 28, 2021 06:30 am ET
MediciNova to Conduct Mouse Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it will conduct a mouse study to investigate the efficacy of...
Jun 22, 2021 10:45 am ET
Thinking about buying stock in Torchlight Energy, Globalstar, MediciNova, Senseonics, or Clean Energy Fuels?
NEW YORK, June 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRCH, GSAT, MNOV, SENS, and CLNE.
Jun 21, 2021 09:31 am ET
Thinking about buying stock in MediciNova, Torchlight Energy, Atossa Therapeutics, Globus Maritime, or ContextLogic?
NEW YORK, June 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MNOV, TRCH, ATOS, GLBS, and WISH.
Jun 21, 2021 06:30 am ET
MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive results from a Phase 2 trial of MN-166 (ibudilast)...
Jun 14, 2021 06:30 am ET
MediciNova to Participate in Maxim Group LLC Fireside Chat
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer,...
Jun 07, 2021 06:30 am ET
MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has initiated a sheep study to investigate MN-166 (ibudilast)...
May 13, 2021 04:30 pm ET
MediciNova Reports First Quarter 2021 Financial Results and Business Update
Received $4M in milestone payments from assignment agreement with Genzyme Corporation - - Strong cash balance of $76M to advance multiple late-stage programs - LA JOLLA, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., (Nasdaq: MNOV,...
May 05, 2021 08:00 pm ET
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Europe
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to Grant from...
Apr 22, 2021 06:30 am ET
MediciNova Receives Gene Therapy Milestone Payments
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received two milestone payments under MediciNova’s...
Apr 19, 2021 06:30 am ET
MediciNova to Participate in the B. Riley Neuroscience Conference
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer,...
Apr 15, 2021 06:30 am ET
MediciNova to Participate in the UBS Global Healthcare Virtual Conference
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will participate in the UBS Global Healthcare...
Mar 09, 2021 04:00 pm ET
MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has partnered with the Biomedical Advanced Research and...
Mar 08, 2021 06:30 am ET
MediciNova to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will present at the Inaugural Emerging Growth...
Mar 03, 2021 06:30 am ET
MediciNova Announces Update on SARS-CoV-2 Vaccine for COVID-19
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an update on the development of a SARS-CoV-2 vaccine for...
Jan 31, 2021 06:00 pm ET
MediciNova Announces Closing of US$20 Million Private Placement Transaction
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the closing of the previously announced private placement...
Jan 18, 2021 06:00 pm ET
MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Japan
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent...
Jan 11, 2021 09:30 pm ET
MediciNova Enters into US$20 Million Securities Purchase Agreement with a fund managed by 3D Investment Partners
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has entered into a Securities Purchase Agreement pursuant...
Dec 29, 2020 06:30 am ET
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent...
Dec 15, 2020 06:30 am ET
MediciNova Added to the NASDAQ Biotechnology Index
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will be added to the NASDAQ Biotechnology Index...
Nov 25, 2020 06:30 am ET
MediciNova Announces Positive Optical Coherence Tomography Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS Published in Multiple Sclerosis Journal
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive Optical Coherence Tomography (OCT) results from the...
Nov 24, 2020 06:30 am ET
MediciNova Announces Initiation of Master Virus Seed Stock Production for its Intranasal COVID-19 Vaccine using BC-PIV Vector Technology
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Good Manufacturing Practice (GMP)-based Master Virus Seed...
Nov 12, 2020 10:00 pm ET
MediciNova Announces Presentation of Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model at The Liver Meeting Digital Experience™ 2020
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Principal Investigators Leila Gobejishvili, PhD and Craig...
Oct 22, 2020 06:30 am ET
MediciNova, in Collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, Announces Plans for a Multi-center, Phase 2b Study to Evaluate MN-166 (ibudilast) in Che
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to initiate a multi-center, placebo-controlled,...
Oct 21, 2020 06:30 am ET
MediciNova Appoints Carolyn Beaver to its Board of Directors and as Audit Committee Chair
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Ms. Carolyn Beaver to its Board of Directors...
Oct 13, 2020 06:30 am ET
MediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience™ 2020
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive findings from a study evaluating MN-001 (tipelukast) in...
Sep 24, 2020 06:30 am ET
MediciNova Announces Positive Clinical Results Regarding MN-166 (ibudilast) for Prevention of Chemotherapy-induced Peripheral Neuropathy Published in Cancer Chemotherapy and Pharmacology
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive clinical findings published in Cancer Chemotherapy and...
Sep 23, 2020 06:30 am ET
MediciNova Announces that its Intranasal COVID-19 Vaccine Successfully Induced Systemic IgG and Mucosal IgA Neutralizing Antibodies Against SARS-CoV-2 in Mice using BC-PIV Vector Technology
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that its intranasal SARS-CoV-2 vaccine prototype for COVID-19,...
Sep 11, 2020 06:30 am ET
MediciNova Announces that BioComo’s Intranasal RS Virus Vaccine Successfully Induced Neutralizing Antibodies against the RS Virus in Mice using BC-PIV Technology
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that BioComo, co-developer of MediciNova’s SARS-CoV-2 vaccine for...
Sep 01, 2020 06:30 am ET
MediciNova Announces Development Progress on Intranasal Formulation of SARS-CoV-2 Vaccine for COVID-19
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced development progress on its intranasal SARS-CoV-2 vaccine for...
Aug 06, 2020 09:31 am ET
Thinking about buying stock in Biocept Inc, MediciNova Inc, Plug Power, IZEA Worldwide, or Teva Pharmaceutical?
NEW YORK, Aug. 6, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOC, MNOV, PLUG, IZEA, and TEVA.
Aug 06, 2020 06:30 am ET
MediciNova Announces the Presentation of Positive Results from Phase 2 Trial of MN‑166 (ibudilast) in Alcohol Use Disorder at the American Psychological Association 2020 Annual Convention
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Principal Investigator, Lara Ray, PhD, Professor at the...
Aug 04, 2020 06:30 am ET
MediciNova to Participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will participate in the Morgan Stanley Virtual...
Jul 27, 2020 06:30 am ET
MediciNova Announces SARS-CoV-2 Vaccine Joint Development with BioComo and Mie University Japan
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an agreement with BioComo (President: Masayuki Fukumura, Mie...
Jul 20, 2020 06:30 am ET
MediciNova to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Geoffrey O'Brien, JD/MBA, Vice President and Executive...
Jul 01, 2020 06:30 am ET
MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) for Prevention of Acute Respiratory Distress Syndrome in Patients with COVID-19
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Investigational New Drug Application (IND) for MN-166...
Jun 25, 2020 07:00 pm ET
MediciNova Announces Positive Preclinical Results Regarding MN-166 (ibudilast) in Glioblastoma (GBM) Published in Frontiers in Immunology
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive preclinical findings published in Frontiers in Immunology...
Jun 23, 2020 07:00 pm ET
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Europe
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to Grant from...
Apr 20, 2020 07:00 pm ET
MediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent...
Apr 08, 2020 06:07 am ET
MediciNova Announces Plans to Initiate a Clinical Trial of MN-166 (ibudilast) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a clinical trial of MN-166 (ibudilast) for...
Mar 09, 2020 07:00 pm ET
MediciNova Announces Plans to Develop MN-166 (ibudilast) for Severe Pneumonia and Acute Respiratory Distress Syndrome (ARDS)
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to initiate development of MN-166 (ibudilast) for...
Feb 17, 2020 06:00 pm ET
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Japan
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent...
Jan 27, 2020 06:00 pm ET
MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to Grant from...
Dec 04, 2019 06:00 pm ET
MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 30th International Symposium on ALS/MND in Perth, Australia
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that additional analyses of MediciNova’s completed clinical trial...
Oct 28, 2019 06:00 am ET
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the Canadian...
Oct 23, 2019 06:00 am ET
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of NAFLD and NASH in Japan
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent...
Oct 07, 2019 07:00 pm ET
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Idiopathic Pulmonary Fibrosis in Japan
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent...
Sep 30, 2019 07:00 pm ET
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Chinese Patent...
Sep 11, 2019 07:00 pm ET
MediciNova to Present at the Ladenburg Thalmann 2019 Healthcare Conference in New York
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer,...
Aug 29, 2019 07:00 pm ET
MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will attend the Morgan Stanley Global Healthcare...
Jul 30, 2019 07:00 pm ET
MediciNova Announces MN-001 Research Collaboration with the National Cerebral and Cardiovascular Disease Research Center in Japan
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a comprehensive research collaboration with...
Jul 29, 2019 07:00 pm ET
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 30th International Symposium on ALS/MND in Perth, Australia
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding MediciNova’s completed clinical trial...
Jul 24, 2019 11:00 pm ET
MediciNova Appoints Kazuko Matsuda to its Board of Directors
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Dr. Kazuko Matsuda to its Board of Directors....
Jul 11, 2019 07:00 pm ET
MediciNova Announces Phase 3 Clinical Trial Plan for MN-166 (ibudilast) in Progressive MS
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced its plans for a Phase 3 clinical trial of MN-166 (ibudilast) in...
Jun 12, 2019 07:00 pm ET
MediciNova to Present at the JMP Securities Life Sciences Conference
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Geoffrey O'Brien, JD/MBA, Vice President and Executive...
Jun 05, 2019 07:00 pm ET
MediciNova Announces Kick-off Meeting to Officially Launch Phase 3 Trial of MN 166 (ibudilast) in ALS
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a kick-off meeting for the Phase 2b/3 clinical trial of...
May 16, 2019 01:14 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of MediciNova, Inc.
Levi & Korsinsky announces it has commenced an investigation of MediciNova, Inc. (NASDAQ: MNOV) concerning possible breaches of fiduciary duty. To obtain additional information, go to: http://www.zlkdocs.com/MNOV-Info-Request-Form-7553 or contact...
May 15, 2019 07:00 pm ET
MediciNova to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Geoffrey O'Brien, JD/MBA, Vice President and Executive...
May 07, 2019 07:00 pm ET
MediciNova Participated in the RECEDE Phase 3 Degenerative Cervical Myelopathy Trial Kick-off Meeting, DCM Symposium and the Official Launch of Myelopathy.org in London, United Kingdom
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced its participation at the Kick-off Meeting for the Phase 3 trial,...
Apr 23, 2019 07:00 pm ET
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the U.S. Patent and...
Apr 15, 2019 07:00 pm ET
MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the U.S. Food and Drug Administration (FDA) has completed...
Apr 03, 2019 07:00 pm ET
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in China
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Chinese Patent...
Apr 01, 2019 07:00 pm ET
MediciNova Announces Results of Subgroup Analysis from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced results from its subgroup analysis of the SPRINT-MS Phase 2b trial...
Mar 24, 2019 07:00 pm ET
MediciNova Announces Upcoming Presentations Regarding the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive Multiple Sclerosis at the 71st American Academy of Neurology Annual Meeting in P
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that additional data from the completed SPRINT-MS Phase 2b trial...
Mar 05, 2019 06:51 pm ET
MediciNova Announces MN-001 Research Collaboration with The Jikei University School of Medicine in Tokyo, Japan
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a comprehensive research collaboration to...
Feb 28, 2019 06:00 pm ET
MediciNova Announces the Publication of Results of the Animal Model Study of MN‑166 (ibudilast) in Glioblastoma in Scientific Reports
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Scientific Reports has published results from the animal...
Jan 21, 2019 06:00 pm ET
MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and other Neurodegenerative
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the U.S. Patent and...
Jan 08, 2019 06:00 pm ET
MediciNova Announces Initiation of Enrollment in a Clinical Trial of MN-166 (ibudilast) in Glioblastoma
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the first glioblastoma patient has enrolled in the clinical...
Jan 07, 2019 06:00 pm ET
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Japan
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent...
Dec 12, 2018 06:00 am ET
MediciNova to Present at the J.P. Morgan Healthcare Conference in San Francisco
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer,...
Oct 04, 2018 07:00 pm ET
MediciNova Announces FDA Grants Orphan Drug Designation to MN-166 (ibudilast) for Glioblastoma
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the U.S. Food and Drug Administration (FDA) has granted...
Sep 25, 2018 07:00 pm ET
MediciNova Announces Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ibudilast) in ALS
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received positive feedback from the FDA (U.S. Food and Drug...
Sep 18, 2018 07:00 pm ET
MediciNova to Present at the Ladenburg Thalmann 2018 Healthcare Conference in New York
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer,...
Sep 04, 2018 07:00 pm ET
MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will attend the Morgan Stanley Global Healthcare...
Aug 29, 2018 05:00 pm ET
MediciNova Announces the Publication of Results of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS in the New England Journal of Medicine
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the New England Journal of Medicine has published results of...
Aug 20, 2018 07:00 pm ET
National Institute on Alcohol Abuse and Alcoholism Awards R01 Research Grant to UCLA for Phase 2b Clinical Trial of MediciNova's MN-166 (ibudilast) in Alcohol Use Disorder
MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the National Institute on Alcohol Abuse and Alcoholism...
Aug 20, 2018 07:50 am ET
Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software — New Horizons, Emerging Trends, and Upcoming Develo
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MediciNova, Inc. (NASDAQ:MNOV), Dermira, Inc. (NASDAQ:DERM), FRP Holdings,...
Aug 06, 2018 07:00 pm ET
MediciNova Announces Initiation of NIHR Grant-Funded Phase 2/3 Trial of MN-166 (ibudilast) for the Treatment of Degenerative Cervical Myelopathy in Collaboration with the University of Cambridge
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it plans to initiate a Phase 2/3 trial of MN-166 (ibudilast)...
Jul 31, 2018 07:00 pm ET
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding MediciNova’s completed clinical trial...
Jul 29, 2018 07:00 pm ET
MediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the ongoing biomarker clinical trial of MN-166 (ibudilast) in...
Jul 09, 2018 07:00 pm ET
MediciNova Announces Clinical Data from Subgroup Analyses of Completed Clinical Trial of MN-166 (ibudilast) in ALS
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced clinical data from ad-hoc subgroup analyses of MediciNova’s...
Jun 19, 2018 07:00 pm ET
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia and Hypercholesterolemia in Japan
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the Japan Patent...
Jun 05, 2018 07:35 am ET
Detailed Research: Economic Perspectives on Galapagos NV, Cellectis S.A, MediciNova, Logitech International S.A, The Descartes Systems Group, and Canadian Pacific Railway — What Drives Growth in Today
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Galapagos NV (NASDAQ:GLPG), Cellectis S.A. (NASDAQ:CLLS), MediciNova, Inc....
May 09, 2018 07:00 pm ET
MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the Investigational New Drug Application (IND) for MN-166...
May 08, 2018 07:00 pm ET
MediciNova to Present at the UBS Global Healthcare Conference in New York
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that MediciNova will present a corporate overview at the UBS Global...
May 07, 2018 07:00 pm ET
MediciNova Announces Plans to Collaborate with UCLA Researchers in Grant-Funded Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder and Withdrawal
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to initiate a clinical trial of MN-166 (ibudilast)...
Apr 26, 2018 07:00 pm ET
MediciNova Announces Additional Data from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 70th Annual Meeting
LA JOLLA, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced that principal investigator Dr. Benjamin...
Apr 24, 2018 06:30 am ET
MediciNova Announces the Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting Plenary Session with Additi
LA JOLLA, Calif., April 24, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Dr. Robert...
Apr 13, 2018 06:30 am ET
MediciNova Announces Presentation of Significant Positive Results from Interim Analysis of the Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD at the International Liver Congress 2018 in Paris, F
LA JOLLA, Calif., April 13, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today presented the positive results from the interim analysis...
Apr 12, 2018 08:20 am ET
Recent Analysis Shows Landmark Infrastructure Partners LP, Laureate Education, MDC Partners, Pzena Investment Management, Dermira, and MediciNova Market Influences — Renewed Outlook, Key Drivers of Gr
NEW YORK, April 12, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Landmark Infrastructure Partners LP (NASDAQ:LMRK), Laureate...
Apr 01, 2018 07:00 pm ET
MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis
LA JOLLA, Calif., April 01, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will terminate the Phase 2...
Mar 29, 2018 06:30 am ET
MediciNova Announces Results of Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence
LA JOLLA, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Phase...
Mar 28, 2018 07:00 pm ET
MediciNova Announces Collaboration with the University of Sydney Concord Cancer Centre to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral Neuropathy
LA JOLLA, Calif., March 28, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it plans to...
Mar 15, 2018 08:15 am ET
Report: Exploring Fundamental Drivers Behind Reading International, Rhythm Pharmaceuticals, Grupo Aeroportuario del Centro Norte S.A.B. de C.V., Golar LNG, Central European Media Enterprises, and Medi
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Reading International Inc (NASDAQ:RDI), Rhythm Pharmaceuticals,...
Mar 12, 2018 07:00 pm ET
MediciNova to Participate in Business Development Panel Session at the BIO Asia International Conference in Tokyo
LA JOLLA, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that MediciNova will participate...
Feb 25, 2018 06:00 pm ET
MediciNova to Present at the Cowen Health Care Conference in Boston
LA JOLLA, Calif., Feb. 25, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will...
Feb 18, 2018 06:00 pm ET
MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, Califo
LA JOLLA, Calif., Feb. 18, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract...
Feb 12, 2018 06:30 pm ET
MediciNova Announces Closing of Underwritten Public Offering of Common Stock
LA JOLLA, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced today the closing of...
Feb 07, 2018 07:12 pm ET
MediciNova Announces Pricing of Underwritten Public Offering of Common Stock
LA JOLLA, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced today the pricing of...
Feb 07, 2018 04:01 pm ET
MediciNova Announces Proposed Underwritten Public Offering of Common Stock
LA JOLLA, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced today that it intends to...
Feb 01, 2018 06:00 pm ET
MediciNova Announces MN-166 (ibudilast) Demonstrated a 26% Reduction in Confirmed Disability Progression in the SPRINT-MS Phase 2b Trial in Progressive MS: Potential Best-in-Disease Drug
LA JOLLA, Calif., Feb. 01, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the presentation of...
Jan 31, 2018 07:00 am ET
MediciNova Announces Presentation of the SPRINT-MS Phase 2b Study of MN-166 (ibudilast) in Progressive MS at the ACTRIMS Forum on February 1, 2018 in San Diego
LA JOLLA, Calif., Jan. 31, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a presentation...
Jan 30, 2018 06:00 pm ET
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California
LA JOLLA, Calif., Jan. 30, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract...
Jan 28, 2018 06:00 pm ET
MediciNova Announces MN-001 (tipelukast) NASH/NAFLD Phase 2 Trial Interim Results Selected for Presentation at the International Liver Congress 2018 in Paris, France
LA JOLLA, Calif., Jan. 28, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding an interim analysis...
Jan 16, 2018 06:00 pm ET
MediciNova to Present at the 98th Annual Meeting of the Chemical Society of Japan
LA JOLLA, Calif., Jan. 16, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova has...
Dec 07, 2017 06:00 pm ET
MediciNova Announces Positive Top-Line Results from the Clinical Trial of MN-166 (ibudilast) in ALS
LA JOLLA, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive top-line results...
Nov 10, 2017 01:30 am ET
MediciNova Appoints Hideki Nagao to its Board of Directors
LA JOLLA, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced the appointment of Mr....
Nov 09, 2017 06:00 pm ET
MediciNova Announces Collaboration with the U.S. Department of Veterans Affairs and Oregon Health & Science University to Evaluate MN-166 (ibudilast) in Methamphetamine Use Disorder
LA JOLLA, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans initiate a biomarker study for evaluating MN-166 (ibudilast) in methamphetamine (MA) use disorder....
Nov 09, 2017 06:00 pm ET
MediciNova Announces Collaboration with the U.S. Department of Veterans Affairs and Oregon Health & Science University to Evaluate MN-166 (ibudilast) in Methamphetamine Use Disorder
LA JOLLA, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans...
Nov 01, 2017 07:00 pm ET
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 28th International Symposium on ALS/MND in Boston, MA, USA
LA JOLLA, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract...
Sep 18, 2017 07:00 pm ET
MediciNova to Present at the Ladenburg Thalmann 2017 Healthcare Conference in New York
LA JOLLA, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017 at 10:00 am at the Sofitel Hotel in New York City.  Management will be available for one-on-one meetings at thi...
Jun 05, 2017 04:00 pm ET
MediciNova Announces Positive Results from a Glioblastoma Animal Model Study Presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois
LA JOLLA, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Associate Professor Kerrie McDonald, Head of the Cure Brain Cancer Foundation Biomarkers and Translational Research Group at the Lowy Cancer Research Centre, University of New South Wales, today presented positive results from an animal model study that examined the potential clinical efficacy of MN-166 (ibudilast) for the treatment of glioblastoma at the 2...
Feb 27, 2017 06:00 pm ET
MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies in Zurich, Switzerland
LA JOLLA, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that Associate Professor Kerrie McDonald, Head of the Cure Brain Cancer Foundation Biomarkers and Translational Research Group at the Lowy Cancer Research Centre, University of New South Wales, will present positive results from an in vitro study that examined the potential clinical efficacy of MN-166 (ibudilast) in combination with temozolomide (TMZ) in patien...
Feb 07, 2017 06:00 pm ET
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 69th Annual Meeting in Boston
LA JOLLA, Calif., Feb. 07, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding MediciNova’s ongoing clinical trial of MN-166 (ibudilast) in ALS (amyotrophic lateral sclerosis) has been accepted for presentation at the American Academy of Neurology (AAN) 69th Annual Meeting to be held April 22-28, 2017 in Boston....
Feb 01, 2017 06:00 pm ET
MediciNova to Attend Mizuho Healthcare Conference in New York
LA JOLLA, Calif., Feb. 01, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will attend the Mizuho Healthcare Conference to be held at the Lotte New York Palace in New York City on March 2-3, 2017.  Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will be available for one-on-one meetings at this conference and investors may request a one-on-one mee...
Jan 23, 2017 06:00 pm ET
MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence
LA JOLLA, Calif., Jan. 23, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the medical journal Neuropsychopharmacology has published a new article on MN-166 (ibudilast) written by Dr. Lara Ray and colleagues at the University of California, Los Angeles.  The article reports that MN-166 (ibudilast) was associated with mood improvements on the stress- and alcohol-cue exposures, as well as reductions in overall craving, depression a...
Dec 20, 2016 06:00 pm ET
MediciNova Announces European Commission Grants Orphan Medicinal Product Designation for MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis
LA JOLLA, Calif., Dec. 20, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the European Commission has granted Orphan Medicinal Product Designation (OMPD) for MN-166 (ibudilast) for the treatment of amyotrophic lateral sclerosis (ALS).  OMPD offers potential benefits including protocol assistance, fee reductions, and 10-year market exclusivity once the medicine is on the market in Europe....
Nov 07, 2016 06:00 pm ET
MediciNova to Attend Global Mizuho Investor Conference in New York
LA JOLLA, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will attend the Global Mizuho Investor Conference to be held at the Omni Berkshire Place in New York City on Monday, November 14, 2016.  Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will be available for one-on-one meetings at this conference and investors may request ...
Oct 30, 2016 07:00 pm ET
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 27th International Symposium on ALS/MND in Dublin, Ireland
LA JOLLA, Calif., Oct. 30, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that an abstract regarding MediciNova’s ongoing clinical trial of MN-166 (ibudilast) in ALS has been accepted for oral presentation at the 27th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) to be held December 7-9, 2016 in Dublin, Ireland.  ...
Oct 11, 2016 07:00 pm ET
MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis
LA JOLLA, Calif., Oct. 11, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to MN-166 (ibudilast) for treatment of Amyotrophic Lateral Sclerosis (ALS).  ...
Sep 25, 2016 07:00 pm ET
Options on MediciNova Common Stock Listed on CBOE
LA JOLLA, Calif., Sept. 25, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Chicago Board Options Exchange (CBOE) has listed options (calls and puts) for MediciNova common stock....
Jul 24, 2016 07:00 pm ET
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis
LA JOLLA, Calif., July 24, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of “fibrosis” which includes a broad range of fibrosis / fibrotic disease in different organs due to different causes....
Jul 13, 2016 06:30 am ET
MediciNova Announces Initiation of Interim Efficacy Analysis in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
LA JOLLA, Calif., July 13, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that 50% of patients (127 out of 255 enrolled patients) have completed the 96-week treatment period in the ongoing Phase 2b clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS). The trial’s external Data Safety Monitoring Board will review the results of an interim efficacy analysis in the fourth quarter of 2016. The purpose ...
Jun 29, 2016 07:00 pm ET
MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louis
LA JOLLA, Calif., June 29, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that researchers at the University of California, Los Angeles (Dr. Lara Ray, Principal Investigator), presented novel findings from further analysis of the completed clinical trial of MN-166 (ibudilast) in alcohol use disorder (AUD) at the 39th Annual Scientific Meeting of the Research Society on Alcoholism on June 27, 2016 at the Hyatt Regency New Orleans in N...
Jun 26, 2016 07:00 pm ET
MediciNova Added to Russell 3000® Index and Russell Global Index
LA JOLLA, Calif., June 26, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the Company has been added to the Russell 3000® Index and the Russell Global Index as a result of the annual Russell index reconstitution.  MediciNova joined the indexes after the U.S. stock market closed on June 24, 2016.  The Russell 3000® Index measures the performance of the stocks of the 3,000 largest U.S. companies.  Russell indexes are widely used b...
May 25, 2016 07:00 pm ET
MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism
LA JOLLA, Calif., May 25, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that two abstracts detailing novel findings from further analysis of the completed clinical trial of MN-166 (ibudilast) in alcohol dependence have been accepted for presentation at the 39th Annual Scientific Meeting of the Research Society on Alcoholism to be held June 25-29, 2016 at the Hyatt Regency New Orleans in New Orleans, LA.  ...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.